EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Cardiac Amyloidosis is Not a Single Disease: A Multiparametric Comparison Between the Light Chain and Transthyretin Forms

Gabriela Neculae, Robert Adam, Andreea Jercan, Sorina Bădeliță, Catherina Tjahjadi, Mirela Draghici, Claudiu Stan, Jeroen J Bax, Bogdan A Popescu, Nina Ajmone Marsan, Daniel Coriu, Ruxandra Jurcuț iD

ESC Heart Failure · 01.10.2024 · 11 (5) · 2825-2834

DOI: 10.1002/ehf2.14852 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift ESC Heart Failure, online erschienen am 16.05.2024. Verfasst von Gabriela Neculae und 11 weiteren Autor:innen. Beteiligte Einrichtung: Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. Hauptthemen laut MEDLINE: Cardiomyopathies. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Competitive Grant Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Systemic amyloidosis represents a heterogeneous group of diseases resulting from amyloid fibre deposition. The purpose of this study is to establish a differential diagnosis algorithm targeted towards the two most frequent subtypes of CA. Methods and results We prospectively included all consecutive patients with ATTR and AL evaluated between 2018 and 2022 in two centres in a score derivation cohort and a different validation sample. All patients had a complete clinical, biomarker, electrocardiographic, and imaging evaluation. Confirmation of the final diagnosis with amyloid typing was performed according to the current international recommendations. The study population included 81 patients divided into two groups: ATTR (group 1, n = 32: 28 variant and 4 wild type) and AL (group 2, n = 49). ATTR patients were younger (50.7 ± 13.9 vs. 60.2 ± 7.3 years, P = 0.0001), and significantly different in terms of NT-proBNP [ATTR: 1472.5 ng/L (97–4218.5) vs. AL 8024 ng/L (3058–14 069) P = 0.001], hs-cTn I [ATTR: 10 ng/L (4–20) vs. AL 78 ng/L (32–240), P = 0.0002], GFR [ATTR 95.4 mL/min (73.8–105.3) vs. AL: 68.4 mL/min (47.8–87.4) P = 0.003]. At similar left ventricular (LV) wall thickness and ejection fraction, the ATTR group had less frequently pericardial effusion (ATTR: 15% vs. AL: 33% P = 0.0027), better LV global longitudinal strain (ATTR: −13.1% ± 3.5 vs. AL: −9.1% ± 4.3 P = 0.04), RV strain (ATTR: −21.9% ± 6.2 vs. AL: −16.8% ± 6 P = 0.03) and better reservoir function of the LA strain (ATTR: 22% ± 12 vs. AL: 13.6% ± 7.8 P = 0.02). Cut-off points were calculated based on the Youden method. We attributed to 2 points for parameters having an AUC > 0.75 (NT-proBNP AUC 0.799; hs-cTnI AUC 0.87) and 1 point for GFR (AUC 0.749) and TTE parameters (GLS AUC 0.666; RV FWS AUC 0.649, LASr AUC 0.643). A score of equal or more than 4 points has been able to differentiate between AL and ATTR (sensitivity 80%, specificity 62%, AUC = 0.798). The differential diagnosis score system was applied to the validation cohort of 52 CA patients showing a sensitivity of 81% with specificity of 77%.

Conclusions

CA is a complex entity and requires extensive testing for a positive diagnosis. This study highlights a series of non-invasive checkpoints, which can be useful in guiding the decision-making process towards a more accurate and rapid differential diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesHumansMaleFemaleMiddle AgedProspective StudiesPrealbuminBiomarkersImmunoglobulin Light-chain AmyloidosisDiagnosis, DifferentialAmyloid Neuropathies, FamilialEchocardiographyElectrocardiographyAgedMagnetic Resonance Imaging, Cine

Stichwörter der Autor:innen

AL amyloidosisATTR amyloidosisCardiac amyloidosisDiagnostic scoreMyocardial deformation

Substanzen

PrealbuminBiomarkers

Autor:innen und Institutionen

  • Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Expert Centre for Rare Cardiovascular Diseases, Prof. Dr. C.C. Iliescu Emergency Institute for Cardiovascular Diseases, Bucharest, Romania.
  • Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania.
  • Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Department of Neurology, Fundeni Clinical Institute, Bucharest, Romania.
  • Department of Nuclear Medicine, Fundeni Clinical Institute, Bucharest, Romania.

ORCID-Profile: Ruxandra Jurcuț

Förderung

  • Pfizer Competitive Grant Program

Zitieren

APA

Neculae, G., Adam, R., Jercan, A., Bădeliță, S., Tjahjadi, C., Draghici, M., Stan, C., Bax, J. J., Popescu, B. A., Marsan, N. A., Coriu, D., & Jurcuț, R. (2024). Cardiac Amyloidosis is Not a Single Disease: A Multiparametric Comparison Between the Light Chain and Transthyretin Forms. ESC Heart Failure, 11(5), 2825-2834. https://doi.org/10.1002/ehf2.14852

Vancouver

Neculae G, Adam R, Jercan A, Bădeliță S, Tjahjadi C, Draghici M, et al. Cardiac Amyloidosis is Not a Single Disease: A Multiparametric Comparison Between the Light Chain and Transthyretin Forms. ESC Heart Failure. 2024;11(5):2825-2834. doi:10.1002/ehf2.14852

BibTeX
@article{Neculae2024,
  author = {Neculae, Gabriela and Adam, Robert and Jercan, Andreea and Bădeliță, Sorina and Tjahjadi, Catherina and Draghici, Mirela and Stan, Claudiu and Bax, Jeroen J and Popescu, Bogdan A and Marsan, Nina Ajmone and Coriu, Daniel and Jurcuț, Ruxandra},
  title = {Cardiac Amyloidosis is Not a Single Disease: A Multiparametric Comparison Between the Light Chain and Transthyretin Forms},
  journal = {ESC Heart Failure},
  year = {2024},
  volume = {11},
  number = {5},
  pages = {2825--2834},
  doi = {10.1002/ehf2.14852}
}
Kostenlos starten →